U.S. Gastrointestinal Point of Care Testing Market Size, Share, Growth, and Regional Forecast, 2025 - 2032

The U.S. gastrointestinal point of care testing (POCT) market is estimated to grow from US$ 926.0 million in 2025 to US$ 1,850.9 million to register a CAGR of 10.4% by 2032. According to the Persistence Market Research report, the rising prevalence of GI disorders, including infections, inflammatory bowel disease, and colorectal cancer, which demand accessible and rapid diagnostic solutions, is fueling the demand. Technological advancements, particularly in molecular diagnostics and immunoassays, have improved the accuracy, speed, and usability of point of care testing, making them ideal for early detection and treatment decisions.

Additionally, the shift toward decentralized, patient-centric healthcare has accelerated point of care testing (POCT) adoption, enabling quicker diagnosis and on-the-spot care across clinical and home settings. Government initiatives further support this trend. The Centers for Disease Control (CDC) highlights that digestive diseases affect millions of Americans annually, emphasizing the urgent need for reliable diagnostic tools. Meanwhile, the Food and Drug Administration (FDA) continues to promote the development and availability of point of care and home-based testing technologies.

Key Industry Highlights

• Assay kits lead the market due to their accuracy, broad application, and quick turnaround times.
• CDC and FDA are promoting preventive screening and expanding POCT accessibility, particularly for colorectal cancer.
• Companies are investing in partnerships, mergers, and acquisitions to strengthen their diagnostic portfolios.
• Over 179 million cases of acute gastroenteritis occur annually in the U.S., driving demand for rapid diagnostics.

Driver - Rising GI Disease Burden and Demand for Rapid Diagnosis Fuels Growth

One of the key drivers of the U.S. gastrointestinal point-of-care testing market is the rising prevalence of gastrointestinal diseases and infections that require rapid diagnosis and timely treatment. According to the Centers for Disease Control and Prevention (CDC), there are approximately 179 million cases of acute gastroenteritis in the U.S. each year. Norovirus alone accounts for an estimated 19 to 21 million illnesses, 109,000 hospitalizations, and nearly 900 deaths annually.

Additionally, bacterial infections such as Clostridioides difficile cause almost 223,900 hospitalizations and 12,800 deaths in the U.S. each year. Point-of-care tests help healthcare providers diagnose these conditions on-site, reducing the time between symptom onset and treatment. This is especially important in emergency departments, urgent care clinics, and long-term care facilities where timely diagnosis limits the spread of infection and improves outcomes. The growing trend toward decentralized healthcare, where patients receive care outside traditional settings increases the demand for portable and easy-to-use diagnostic tests. As the awareness of colorectal cancer screening increases through fecal immunochemical tests (FIT), the clinical demand for POCT procedures underscores the significance.

Restraint - Accuracy Concerns and Regulatory Hurdles

A key restraint in the U.S. gastrointestinal point-of-care testing market is the limited accuracy in the sensitivity and specificity of certain rapid diagnostic tests. While POCT offers convenience and speed, some tests may produce false positives or negatives, leading to misdiagnosis or delayed treatment. This can undermine clinician confidence and reduce adoption in critical care settings. Moreover, despite advancements, not all POCT devices are capable of detecting a wide range of pathogens simultaneously, limiting their use in complex gastrointestinal cases.

Regulatory challenges also act as a barrier, as approval processes for new diagnostic tools can be lengthy and complex. Reimbursement policies for POCT are not uniform across payers, and inadequate coverage may deter healthcare providers from integrating these tools into routine care. Additionally, initial costs of acquiring advanced POCT platforms can be high, especially for smaller practices and rural clinics, further limits market penetration.

Opportunity - Technological Innovation and Preventive Care Trends Create Strong Growth Opportunities

The U.S. gastrointestinal point-of-care testing market presents strong growth opportunities through advancements in diagnostic technology and the increasing shift toward decentralized healthcare. One major opportunity lies in developing smartphone-compatible and digital POCT solutions, which enhance accessibility and allow patients to conduct tests at home with real-time results shared with healthcare providers. The growing popularity of telehealth services also creates a favorable environment for integrating POCT into remote care. Additionally, the emphasis on preventive healthcare and early disease detection supports the demand for non-invasive, easy-to-use tests such as fecal immunochemical tests (FIT) for colorectal cancer screening.

Expanding awareness campaigns and government-backed screening programs further drive interest in early diagnosis. Moreover, underserved rural and community health settings offer untapped potential for point-of-care diagnostic expansion, as these areas often lack access to centralized laboratories. Together, these trends highlight the market's potential for innovation and wider adoption across diverse healthcare environments.

Product Type Insights

In the U.S., gastrointestinal point-of-care testing assay kits are expected to lead the by a 41.4% market share in 2025, primarily due to their accuracy, reliability, and broad application in detecting various GI conditions such as H. pylori, Clostridioides difficile, and Salmonella. These kits, which include rapid immunoassays and molecular diagnostic tools are widely used across hospitals, clinics, and even home settings due to their convenience and ability to deliver quick results. Additionally, dipsticks represent the fastest growing segment, particularly for fecal occult blood testing (FOBT), a common non-invasive method for colorectal cancer screening. Their affordability and simplicity make them accessible in primary care and community health environments, although technological limitations have slowed their growth compared to newer formats.

Furthermore, cassette-based tests, often built on lateral flow assay technology, are rapidly gaining momentum as the second fast-growing. Their user-friendly design and minimal sample preparation requirements make them ideal for urgent care, physician offices, and telemedicine kits.

Indication Insights

Gastrointestinal point-of-care testing in the U.S. is primarily driven by the need to quickly identify and manage infectious diseases. Bacterial infections, such as those caused by Clostridioides difficile, Salmonella, and Helicobacter pylori, account for a large share of diagnostic demand due to their severity and potential complications. Viral infections, especially those caused by Norovirus and Rotavirus, are widespread and highly contagious, contributing to millions of cases each year. These infections often lead to outbreaks in schools, long-term care facilities, and other communal environments, highlighting the necessity of fast, on-site testing.

Parasitic infections, though less prevalent, remain important for specific populations, including travelers and immunocompromised individuals. Pathogens such as Giardia lamblia and Cryptosporidium require targeted diagnostics, particularly in clinical and public health settings. Additionally, colorectal cancer screening using fecal immunochemical tests (FIT) is gaining traction for early detection. These various indications underscore the critical role of accessible diagnostics in both treatment and prevention.

The U.S. gastrointestinal point of care testing (POCT) market is moderately competitive, with a mix of established diagnostic companies and emerging players. Leading firms such as Abbott Laboratories, QuidelOrtho Corporation, Bio-Rad Laboratories, and Thermo Fisher Scientific dominate due to their extensive product portfolios, technological innovation, and strong distribution networks. These companies focus on developing rapid, accurate, and easy-to-use diagnostic kits and devices that cater to the growing demand in clinical and home settings.

Mid-sized players and startups are also entering space, offering specialized tests and niche technologies such as microfluidics and smartphone-enabled diagnostics. Strategic partnerships, acquisitions, and continuous R&D investment are common strategies used to gain a competitive edge. Additionally, companies are aligning their offerings with regulatory guidelines to ensure faster approvals and broader market access. As demand for decentralized healthcare grows, the competition is expected to intensify with innovation and cost-effectiveness becoming key differentiators in the market.

Key Industry Developments

• In August 2024, MP Biomedicals launched a new line of in vitro diagnostic kits utilizing immunochromatographic technology to identify gastrointestinal pathogens. These tests are specifically designed to detect Helicobacter pylori, Salmonella typhi, and Vibrio cholerae serogroups O1 and O139.
• In February 2024, Reese Pharmaceutical launched ColoTest, an FDA-approved over-the-counter fecal immunochemical test (FIT) for at-home use. The test is designed to detect hidden blood in the stool, which can be an early warning sign of colorectal cancer and other gastrointestinal conditions.